Plaque-Derived FFRCT – the only FFRCT with Plaque Concordance – Planned for FDA Submission in Q4-25

Elucid to Showcase PlaqueIQ at SCCT 2025

Opportunity to demo the only FDA-cleared, non-invasive plaque analysis based on objective ground truth histology, the gold standard for characterization of plaques BOSTON – July 10, 2025 – Elucid, an AI medical technology company focused on providing physicians with a...